1. [Metabolic disorders as paraneoplastic syndromes].
- Author
-
Krug S and Michl P
- Subjects
- Cross-Sectional Studies, Diagnosis, Differential, Humans, Hypercalcemia diagnosis, Hypercalcemia epidemiology, Hypercalcemia therapy, Hypoglycemia diagnosis, Hypoglycemia epidemiology, Hypoglycemia therapy, Metabolic Diseases epidemiology, Metabolic Diseases therapy, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms therapy, Paraneoplastic Syndromes epidemiology, Paraneoplastic Syndromes therapy, Parathyroid Hormone-Related Protein blood, Prognosis, Risk Factors, Tumor Lysis Syndrome diagnosis, Tumor Lysis Syndrome epidemiology, Tumor Lysis Syndrome therapy, Metabolic Diseases diagnosis, Paraneoplastic Syndromes diagnosis
- Abstract
Paraneoplastic syndromes are characterized by the tumor-induced release of peptide hormones and/or the initiation of immune phenomena, which elicit clinical changes and alterations in laboratory parameters independent of the tumor size and spread. In addition to neurological, endocrinal and rheumatological phenotypes, metabolic alterations play a special role in the clinical routine as they commonly present with acute symptoms in an emergency situation and necessitate immediate diagnosis and prompt initiation of treatment. Metabolic alterations within the framework of malignant diseases should be treated in a multidisciplinary team and it is often necessary to perform monitoring and treatment in an intensive care unit. This article focuses on the diagnostic and therapeutic options for metabolic disorders due to paraneoplastic syndromes, such as hypercalcemia, hypocalcemia, hyperglycemia, hypoglycemia and a special variant of tumor-induced metabolic disorders due to tumor lysis syndrome.
- Published
- 2018
- Full Text
- View/download PDF